A carregar...
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...
Na minha lista:
| Publicado no: | Med Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5366170/ https://ncbi.nlm.nih.gov/pubmed/28343336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0928-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|